Evogene Raises $3.4 Million Through Immediate Warrant Exercise and New Warrant Issuance

Reuters

Feb 11

Evogene Raises $3.4 Million Through Immediate Warrant Exercise and New Warrant Issuance

Evogene Ltd. has announced a warrant inducement agreement with an existing institutional investor, resulting in the immediate exercise of August 2024 Series A and Series B ordinary warrants to purchase up to 1,692,308 ordinary shares each. The warrants were exercised at a reduced price of $1.00 per share, generating approximately $3.4 million in gross proceeds for the company before fees and expenses. In return, the investor will receive new Series A-1 and Series B-1 unregistered warrants to purchase up to 2,538,462 ordinary shares each, with exercise prices of $1.25 per share. The new warrants will be immediately exercisable, with the Series A-1 warrants expiring in five years and the Series B-1 warrants expiring in eighteen months. Net proceeds will be used for working capital and general corporate purposes. A.G.P./Alliance Global Partners acted as the sole financial advisor for the transaction.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Evogene Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: LN84992) on February 10, 2026, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2610662002"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2610662002\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2610662002?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-11 02:20","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2610662002","market":"fut","top_or_hot":-1,"title":"Evogene Raises $3.4 Million Through Immediate Warrant Exercise and New Warrant Issuance","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Evogene Raises $3.4 Million Through Immediate Warrant Exercise and New Warrant Issuance\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/EVGN\">Evogene Ltd.</a> has announced a warrant inducement agreement with an existing institutional investor, resulting in the immediate exercise of August 2024 Series A and Series B ordinary warrants to purchase up to 1,692,308 ordinary shares each. The warrants were exercised at a reduced price of $1.00 per share, generating approximately $3.4 million in gross proceeds for the company before fees and expenses. In return, the investor will receive new Series A-1 and Series B-1 unregistered warrants to purchase up to 2,538,462 ordinary shares each, with exercise prices of $1.25 per share. The new warrants will be immediately exercisable, with the Series A-1 warrants expiring in five years and the Series B-1 warrants expiring in eighteen months. Net proceeds will be used for working capital and general corporate purposes. A.G.P./Alliance Global Partners acted as the sole financial advisor for the transaction.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Evogene Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: LN84992) on February 10, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Evogene Raises $3.4 Million Through Immediate Warrant Exercise and New Warrant Issuance</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEvogene Raises $3.4 Million Through Immediate Warrant Exercise and New Warrant Issuance\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-02-11 02:20</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Evogene Raises $3.4 Million Through Immediate Warrant Exercise and New Warrant Issuance\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/EVGN\">Evogene Ltd.</a> has announced a warrant inducement agreement with an existing institutional investor, resulting in the immediate exercise of August 2024 Series A and Series B ordinary warrants to purchase up to 1,692,308 ordinary shares each. The warrants were exercised at a reduced price of $1.00 per share, generating approximately $3.4 million in gross proceeds for the company before fees and expenses. In return, the investor will receive new Series A-1 and Series B-1 unregistered warrants to purchase up to 2,538,462 ordinary shares each, with exercise prices of $1.25 per share. The new warrants will be immediately exercisable, with the Series A-1 warrants expiring in five years and the Series B-1 warrants expiring in eighteen months. Net proceeds will be used for working capital and general corporate purposes. A.G.P./Alliance Global Partners acted as the sole financial advisor for the transaction.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Evogene Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: LN84992) on February 10, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260210:nNDL5SwrJk:1","article_id":"2610662002","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2610662002","pubTimestamp":1770747615,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Evogene Ltd. has announced a warrant inducement agreement with an existing institutional investor, resulting in the immediate exercise of August 2024 Series A and Series B ordinary warrants to purchase up to 1,692,308 ordinary shares each. The warrants were exercised at a reduced price of $1.00 per share, generating approximately $3.4 million in gross proceeds for the company before fees and expenses. In return, the investor will receive new Series A-1 and Series B-1 unregistered warrants to purchase up to 2,538,462 ordinary shares each, with exercise prices of $1.25 per share. The new warrants will be immediately exercisable, with the Series A-1 warrants expiring in five years and the Series B-1 warrants expiring in eighteen months. Net proceeds will be used for working capital and general corporate purposes. A.G.P./Alliance Global Partners acted as the sole financial advisor for the transaction.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","EVGN":"Evogene Ltd."},"translate_title":"Evogene通过立即行使认股权证和发行新认股权证筹集340万美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"EVGN":0.9},"content_text":"Evogene Raises $3.4 Million Through Immediate Warrant Exercise and New Warrant Issuance\n    \n\nEvogene Ltd. has announced a warrant inducement agreement with an existing institutional investor, resulting in the immediate exercise of August 2024 Series A and Series B ordinary warrants to purchase up to 1,692,308 ordinary shares each. The warrants were exercised at a reduced price of $1.00 per share, generating approximately $3.4 million in gross proceeds for the company before fees and expenses. In return, the investor will receive new Series A-1 and Series B-1 unregistered warrants to purchase up to 2,538,462 ordinary shares each, with exercise prices of $1.25 per share. The new warrants will be immediately exercisable, with the Series A-1 warrants expiring in five years and the Series B-1 warrants expiring in eighteen months. Net proceeds will be used for working capital and general corporate purposes. A.G.P./Alliance Global Partners acted as the sole financial advisor for the transaction.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Evogene Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: LN84992) on February 10, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}